Intellia Therapeutics
NTLA
10.00
+0.48
+5.04%
Intellia Therapeutics
US · NTLA
#2899 by market cap
Listed 2016
10.00
+0.48
+5.04%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 10 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.9 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 103.74% -0.91pp
- Institutions
- 382 -10
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund72.29%
Hedge Fund16.46%
Public Company7.92%
VC/PE Fund3.48%
Private Company2.73%
Individual/Insider1.57%
Government Pension Fund0.45%
Insurance Company0.26%
Family Office/Trust0.14%
Top holders as of 2026-09-30
BlackRock
11.42% · 16.04M sh
ARK Investment Management LLC
11.35% · 15.93M sh
State Street Global Advisors
5.56% · 7.81M sh
Vanguard Portfolio Management, LLC
5.26% · 7.39M sh
D. E. Shaw & Co., L.P.
4.59% · 6.44M sh
Vanguard Capital Management, LLC
4.30% · 6.04M sh
Two Sigma Investments, LP
3.73% · 5.24M sh
FMR
3.34% · 4.68M sh
RA Capital Management, L.P.
3.23% · 4.53M sh
Regeneron Pharmaceuticals, Inc.
2.64% · 3.70M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| John Leonard | Chief Executive Officer | 0.85% |
| Fred Cohen | Independent Director | 0.14% |
| Edward Dulac | Chief Financial Officer | 0.11% |
| William Chase | Independent Director | 0.10% |
| Eliana Clark | Former Executive VP & Chief Technical Officer | 0.07% |
| David Lebwohl | Former Chief Medical Officer | 0.06% |
| James Basta | General Counsel | 0.05% |
| Birgit Schultes | Chief Scientific Officer | 0.05% |
| Michael Dube | Vice President | 0.05% |
| Derek Hicks | Executive VP & Chief Business Officer | 0.04% |
| Laura Sepp-Lorenzino | Former Advisor | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-01 | John Leonard | Chief Executive Officer | Automatic Disposition | -9,000 | $11.99 |
| 2026-10-25 | Jing Marantz | EVP & Chief Medical Officer | Other Acquisition | +199,822 | -- |
| 2026-10-25 | Jing Marantz | EVP & Chief Medical Officer | Other Derivative Acquisition | +275,061 | $11.26 |
| 2026-10-01 | Michael Dube | Vice President | Open Market Disposition | -1,864 | $12.43 |
| 2026-08-20 | John Leonard | Chief Executive Officer | Automatic Disposition | -22,675 | $12.60–13.00 |
| 2026-08-19 | John Leonard | Chief Executive Officer | Intent to Sell (Form 144) | -22,675 | $12.95 |
| 2026-07-21 | Edward Dulac | Chief Financial Officer | Open Market Disposition | -8,111 | $11.25 |
| 2026-07-01 | Edward Dulac | Chief Financial Officer | Automatic Disposition | -4,677 | $18.00 |
| 2026-06-30 | Michael Dube | Vice President | Open Market Disposition | -2,641 | $16.78 |
| 2026-06-08 | Fred Cohen | Independent Director | Other Acquisition | +9,200 | -- |
| 2026-06-08 | Fred Cohen | Independent Director | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-06-08 | Franciscus A. G. Verwiel | Independent Chairperson | Other Acquisition | +9,200 | -- |
| 2026-06-08 | Franciscus A. G. Verwiel | Independent Chairperson | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-06-08 | William Chase | Independent Director | Other Acquisition | +9,200 | -- |
| 2026-06-08 | William Chase | Independent Director | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-06-08 | Brian Goff | Independent Director | Other Acquisition | +9,200 | -- |
| 2026-06-08 | Brian Goff | Independent Director | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-06-08 | Jesse Goodman | Independent Director | Other Acquisition | +9,200 | -- |
| 2026-06-08 | Jesse Goodman | Independent Director | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-06-08 | Georgia Keresty | Independent Director | Other Acquisition | +9,200 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:29 · For reference only, not investment advice and not tailored to your situation.
Intellia Therapeutics discussion 0 comments